Abemaciclib

VERZENIO®

Overview

Abemaciclib is an experimental therapy being developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.

SparkCures ID 325
Developed By Eli Lilly and Company
Brand Name Verzenio®
Generic Name Abemaciclib
Treatment Classifications

Clinical Trials

Resources

There are no resources, links or videos to display for this treatment.